Full Name
Dr. Pier Luigi Zinzani MD, PhD
Job Title
Professor of Hematology
Company/Affiliation
University of Bologna
Speaker Bio
Dr. Pier Luigi Zinzani attended the University of Bologna (specialty in Hematology with honors) and was awarded a “Post-Doctoral Fellowship in Medical Oncology” released by the “Roger Williams Cancer Center” of Providence (USA) in 1989. He is a member of several scientific societies as the Italian Society of Hematology, the Italian Society of Experimental Hematology, the American Society of Hematology and the American Society of Clinical Oncology. He is the Principal Investigator of more of 150 clinical trials. Currently, Dr. Zinzani is Associate Professor of Medicine Hematology and Chief of the clinical and translational program of the Lymphoma Unit at the Institute of Hematology and Medical Oncology “L. e A. Seràgnoli” University of Bologna, Italy.
Dr. Zinzani has authored over 500 medical publications and abstracts and has contributed to over 15 texts. He is Associate Editor of Annals of Oncology. He is also on the editorial board of numerous journals. He has served on several committees of the Italian Society of Hematology and of The Italian Foundation of Lymphomas. Since 1995 he has been a stage (142) and international congress (18) organizer and manages their scientific secretariat. His current research interest includes clinical trial methodology, prognostic factors in NHL, Hodgkin’s disease, chronic lymphocytic leukemia, new drug development, and hairy cell leukemia.
Dr. Zinzani has authored over 500 medical publications and abstracts and has contributed to over 15 texts. He is Associate Editor of Annals of Oncology. He is also on the editorial board of numerous journals. He has served on several committees of the Italian Society of Hematology and of The Italian Foundation of Lymphomas. Since 1995 he has been a stage (142) and international congress (18) organizer and manages their scientific secretariat. His current research interest includes clinical trial methodology, prognostic factors in NHL, Hodgkin’s disease, chronic lymphocytic leukemia, new drug development, and hairy cell leukemia.
Speaking At
